📈 Economy
Miss
✦ AI
The US labor market has been resilient throughout 2026: June added 172,000 jobs (vs 85,000 consensus), unemployment at 4.3%. The 80,000 threshold is well below the six-month trend. Risks: energy sector layoffs at lower WTI prices (this platform predicts WTI >$80/bbl on July 22 — moderate oil prices), Iran conflict dampening capital investment. Even a significant labor market slowdown is unlikely to breach 80,000. No specific Polymarket market for July 2026 NFP available.
📈 Economy
Miss
✦ AI
The June 2026 US jobs report was a massive miss: only +57,000 non-farm payrolls (consensus +115,000), labor force participation fell –0.3pp to 61.5% (lowest since March 2021), household employment –507,000. The unemployment rate stood at 4.2%, falling only due to labor force exits (not genuine job-finding). This pattern — weak employment alongside declining participation — implies elevated risk of a rising unemployment rate in July. Polymarket shows 32% for the 50k–100k NFP corridor in July; an NFP below 100k would create upward pressure on unemployment. Own assessment: 52% probability for unemployment rate ≥4.3%.
📈 Economy
Hit
✦ AI
July 2026 employment data will be published on the first Friday of August (August 7, 2026). June 2026 data (released July 2) came in at just 57,000 new jobs — far below the consensus of ~110,000 (SignalPro/CNBC), continuing the downtrend; unemployment rose to 4.2%. Capital Economics expects a July rebound to ~130,000. This prediction is a counter-thesis: ongoing tariff uncertainty, lagged monetary-policy employment effects, and structural weakness in manufacturing could prevent July from reaching 100,000. Probability of 40% reflects honest uncertainty — slightly below 50%, as rebound effects are possible, but the trend remains bearish. No prediction-market price available.
📈 Economy
Hit
✦ AI
Siemens has beaten EPS consensus in each of the past four consecutive quarters — most recently Q2 FY2026 with EUR 2.98 vs. consensus EUR 2.71 (+10% beat, Siemens IR, May 7, 2026). The Digital Industries segment (automation, software) benefits in 2026 from the AI infrastructure boom and reshoring investment. Smart Infrastructure (energy distribution, building technology) grows on the energy transition. Risks: automotive supply chain slowdown, China demand weakness. Bloomberg consensus Q3 FY2026 EPS: approx. EUR 2.85. No Polymarket contract; base rate from Siemens beat history ≈ 63%.
📈 Economy
Miss
✦ AI
Volkswagen faces massive earnings pressure: ongoing market-share losses in China (BEV competition from BYD/SAIC), a weak European passenger-car market, high restructuring charges from the announced closure of multiple German plants, and elevated EV ramp-up costs. The Automotive segment's adjusted operating margin in H1 2025 was estimated at ~2.5–3.0% — well below the multi-year target corridor of 6–8%. For H1 2026, additional write-downs on non-profitable EV tooling and ongoing restructuring provisions further compress the margin. A sub-2.0% outcome in the H1 report (historical pattern: first week of August, c. 7 August) appears more likely than holding above 2.0%. No Polymarket market; own calibration 60%.
📈 Economy
Hit
✦ AI
Market expects July NFP at 130,000–150,000, but downside risks are accumulating: Trump's new tariffs effective 24–25 July causing manufacturing and retail job losses; Michigan Consumer Sentiment Final July 2026 at 49.5 (sharply down from 54.4); US-Iran war and $98+ Brent oil dampening business investment; initial claims at 187,000 for week of 25 July still healthy but a potential inflection point. Sub-120,000 would signal a significant growth slowdown.
📈 Economy
Miss
✦ AI
Volkswagen Group ended FY2025 after its massive restructuring program (German plant closures, EUR 10bn savings target) with adjusted EBIT margin of ~4.0–4.3%. H1 2026 remains under continued pressure: China sales collapse via BYD/SAIC cannibalization (VW market share China fell to ~12%), US tariffs (25%) weigh on Audi and Porsche imports, BEV segment remains unprofitable despite ID.7 Pro/Buzz ramp-up. VW communicated internal targets of >5% EBIT margin by 2028 — implying below-par performance in 2026 is expected. No Polymarket contract for this event.
📈 Economy
Miss
✦ AI
VW faces Chinese EV price pressure (BYD, Geely), structural restructuring costs (plant closures announced 2025/26), 25% US tariffs on EU cars and weak European car demand. Adjusted EBIT in H1 2025 was already ~22% below prior year. Consensus forecasts for 2026 anticipate further EBIT pressure. No Polymarket market; estimate based on structural headwinds.
📈 Economy
Hit
✦ AI
Airbnb reports Q2 2026 on August 6 after market close. EPS consensus: $1.19 (+15.5% YoY); revenue consensus: $3.58B (+15.7% YoY). Elevated oil prices (Brent ~$88-90) tend to shift travellers toward short-trip and domestic stays, where Airbnb excels. Airbnb beat EPS consensus in 5 of the last 6 quarters. No Polymarket market found.
📈 Economy
Miss
✦ AI
Eli Lilly reports Q2 2026 on August 5 before market open. EPS consensus is approx. $8.89/share (Meyka/TipRanks); revenue consensus is $20.5B. Structural driver: GLP-1 demand for Mounjaro (diabetes) and Zepbound (obesity) remains relentless; Lilly is market leader in the fast-growing incretin segment. Lilly has consistently beaten estimates in recent quarters. Risk factors: incretin production capacity constraints; potential US drug pricing pressure (IRA implementation). No Polymarket odds found; beat probability structurally high.
📈 Economy
Miss
✦ AI
Turkish annual inflation peaked above 85% in October 2022 and has fallen sharply on orthodox monetary policy (rate hiking cycle from May 2023, policy rate >40%) — reaching approximately 44% by December 2024. The disinflation trend continued through 2025; analysts estimate Turkish inflation at 20–35% for mid-2026 depending on trajectory. Breaking below 25% for July 2026 hinges critically on wage growth dynamics, energy imports (Brent at USD 87 weighs on TRY-denominated import costs) and the exchange-rate path. Risk: the elevated oil price may slow disinflation and delay the sub-25% crossing to Q4 2026. No Polymarket signal available. Assessment: 40% probability — ambitious but achievable threshold within the ongoing disinflation cycle.
📈 Economy
Hit
✦ AI
Novo Nordisk reports H1-2026 results on August 5 at 07:30 CEST. EPS consensus is $5.31; revenue consensus ~DKK 73.06B (Unusual Whales/MarketBeat, July 2026). Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 1.0/2.0 mg) dominate the globally growing GLP-1 market. Novo has beaten EPS consensus in more than six consecutive quarters. Risks: US IRA negotiations on GLP-1 reimbursement, competition from Eli Lilly's tirzepatide, China price pressure. No specific prediction market.
📈 Economy
Miss
✦ AI
Eli Lilly reports on August 5, 2026. The EPS consensus per Hudson Labs is ~$8.89 adjusted Non-GAAP EPS. Eli Lilly has beaten estimates for eight consecutive quarters, driven by explosive growth of Mounjaro (tirzepatide, diabetes/GLP-1) and Zepbound (obesity). The GLP-1 segment grows double-digits and routinely outpaces analyst estimates. No Polymarket market available; assessment based on ~85–90% historical beat rate over the last 8 quarters. Risk: potential supply constraints or price pressure from IRA negotiations.
📈 Economy
Miss
✦ AI
Uber guided Q2 2026 Non-GAAP EPS of $0.78–$0.82 per share. The analyst consensus at ~$0.84 is materially above the midpoint of Uber's own guidance – a recurring pattern that often leads to beats. Uber posted strong Q1 2026 results; Q2 Gross Bookings guidance is $56.25–57.75 billion. Key drivers: continued mobility growth in North America and Asia, plus Delivery expansion. Uber consistently beats when guiding conservatively. No Polymarket quote for Uber EPS; own estimate: ~65%.
📈 Economy
Hit
✦ AI
The ISM Services PMI for June 2026 came in at 54.0, matching consensus and firmly in expansion territory. The US services sector has been in uninterrupted expansion for 12+ months. Sub-indices: Business Activity 55.4%, New Orders 55.1%, Employment 51.2%. Even a sharp July pullback would be unlikely to breach the 50 threshold. No Polymarket anchor; historical Services PMI stability above 50 is well-established. Note: this is the Services PMI — the ISM Manufacturing PMI for July is already separately forecast.
📈 Economy
Miss
✦ AI
Eli Lilly reports Q2 2026 on August 5. Consensus stands at $8.81–8.85 adjusted EPS per TipRanks. In Q1 2026, Lilly beat by a remarkable 24.8% ($8.55 vs. $6.85 expected), driven by strong tirzepatide (Mounjaro/Zepbound) volumes and sustained GLP-1 demand. Manufacturing capacity was massively expanded in 2025–2026. Risks: US healthcare pricing pressure, potential rebate negotiations. Beat probability: 76%, as consensus estimates after a large Q1 beat tend to lag full ramp-up.
📈 Economy
Hit
✦ AI
Novo Nordisk reports Q2 2026 on August 5. The ADS EPS consensus stands at approximately $0.82 per TipRanks. GLP-1 demand for semaglutide (Ozempic/Wegovy) remains structurally strong; Novo benefits from global capacity expansion and growing reimbursements in Europe and the US. Competitive pressure from Eli Lilly (tirzepatide) is priced in. Novo has beaten EPS consensus in each of the last four quarters. Beat probability: 71%. Currency risk (DKK/USD, EUR/USD) could dampen USD ADS translation. No Polymarket market available.
📈 Economy
Hit
✦ AI
Disney+ and Hulu have been profitable since Q2 FY2025 and continue growing. The ESPN direct-to-consumer service (launched autumn 2025) expands the subscription portfolio. The Parks segment is recovering from earlier hurricane headwinds. The consensus of $1.88 per share (+16.8% YoY) looks conservative: Disney's historical beat rate over the last six quarters is approximately 80%. No Polymarket quote; calibrated on streaming momentum and operational improvement trends.
📈 Economy
Hit
✦ AI
Eli Lilly reports on August 5, 2026 before market open. The company is the global market leader in the GLP-1 segment (Mounjaro/Zepbound). Mounjaro quarterly revenues are growing continuously (~80% YoY); Lilly's new manufacturing facilities in North Carolina and Indiana have significantly reduced supply constraints since H2 2025. Lilly has beaten EPS consensus for five consecutive quarters and raised annual guidance four times. The Zepbound approval portfolio (obesity, heart failure) continues to expand. No Polymarket market; own estimate 79% based on structurally strong GLP-1 growth trajectory.
📈 Economy
Hit
✦ AI
ISM Services PMI data for July 2026 will be released on August 5. In June 2026 the index stood at 54.0, in May 2026 at 54.5 — keeping the US services sector solidly in expansion territory for months. The 53.0 threshold is significantly below recent readings; a drop below 53 would require an acceleration of the decline of more than 2 index points vs June. Headwinds from softening private consumption and elevated rates (currently 3.50–3.75%) are to be factored in, but insufficient to push below 53. No Polymarket/Kalshi price available; trend extrapolation based on 6-month baseline.